期刊
MOLECULAR THERAPY
卷 28, 期 5, 页码 1276-1286出版社
CELL PRESS
DOI: 10.1016/j.ymthe.2020.03.004
关键词
-
资金
- FAPESP-CEPID [2013/08028-1]
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) [001]
- CNPq, Brazil [309206/2011-1, 444722/2014-9]
- INCT-CETGEN, Brazil [573633/2008-8]
- FINEP-CTC, Brazil [0108057900]
Malignant brain tumors are among the most aggressive cancers with poor prognosis and no effective treatment. Recently, we reported the oncolytic potential of Zika virus infecting and destroying the human central nervous system (CNS) tumors in vitro and in immunodeficient mice model. However, translating this approach to humans requires pre-clinical trials in another immunocompetent animal model. Here, we analyzed the safety of Brazilian Zika virus (ZIKV(BR)) intrathecal injections in three dogs bearing spontaneous CNS tumors aiming an anti-tumoral therapy. We further assessed some aspects of the innate immune and inflammatory response that triggers the anti-tumoral response observed during the ZIKV(BR) administration in vivo and in vitro. For the first time, we showed that there were no negative clinical side effects following ZIKV(BR) CNS injections in dogs, confirming the safety of the procedure. Furthermore, the intrathecal ZIKV(BR) injections reduced tumor size in immunocompetent dogs bearing spontaneous intracranial tumors, improved their neurological clinical symptoms significantly, and extended their survival by inducing the destruction specifically of tumor cells, sparing normal neurons, and activating an immune response. These results open new perspectives for upcoming virotherapy using ZIKV to destroy and induce an anti-tumoral immune response in CNS tumors for which there are currently no effective treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据